• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Oncotarget DOT1L inhibition is lethal for multiple myeloma due to perturbation

Bioengineer by Bioengineer
March 20, 2020
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Oncotarget Volume 11, Issue 11 reported that in order to understand the molecular mechanism of the dependency in MM, the research team examined gene expression changes upon DOT1L inhibition in sensitive and insensitive cell lines and discovered that genes

IMAGE

Credit: Correspondence to – Ralph Tiedt – [email protected]


Oncotarget Volume 11, Issue 11 reported that in order to understand the molecular mechanism of the dependency in MM, the research team examined gene expression changes upon DOT1L inhibition in sensitive and insensitive cell lines and discovered that genes belonging to the endoplasmic reticulum stress pathway and protein synthesis machinery were specifically suppressed in sensitive cells.

Whole-genome CRISPR screens in the presence or absence of a DOT1L inhibitor revealed that concomitant targeting of the H3K4me3 methyltransferase SETD1B increases the effect of DOT1L inhibition.

Dr. Ralph Tiedt from Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland said, “MM is an aggressive hematologic cancer characterized by the monoclonal expansion of plasma cells secreting high amounts of immunoglobulins.“

“MM is an aggressive hematologic cancer characterized by the monoclonal expansion of plasma cells secreting high amounts of immunoglobulins.”

– Dr. Ralph Tiedt, Novartis Institutes for BioMedical Research (NIBR) Oncology

The sensitivity of MM cells to proteasome inhibitors is thought to be due to perturbation of the hyperactive UPR, which may offer some degree of selectivity versus non-cancerous cells.

Through pharmacologic and genetic approaches, we found that inhibition of DOT1L, an H3K79 methyltransferase, profoundly reduces the viability of a subset of MM cell lines in vitro and inhibits the growth of established MM xenografts in mice.

CRISPR screens further revealed that targeting the histone methyltransferase SETD1B concomitantly with DOT1L further enhances this effect on the UPR and increases and accelerates MM cell death.

The Tiedt Research Team concluded in their Oncotarget Research Paper, “our discovery indicates a novel opportunity for DOT1L inhibitors in cancer treatment. Concomitant targeting of SETD1B enhances phenotypic and transcriptional effects of DOT1L inhibition in sensitive MM cell lines, which may be an additional therapeutic angle. To our knowledge, no selective SETD1B inhibitors have been described yet, and our data questions whether its methyltransferase activity is critical in the MM context. Additional work is needed to address this question and guide drug discovery.“

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.27493

Full text – http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=27493&path[]=90094

Correspondence to – Ralph Tiedt – [email protected]

Media Contact
@RYANJAMESJESSUP
[email protected]
202-638-9720

Original Source

http://www.oncotarget.com/news/pr/dot1l-inhibition-is-lethal-for-multiple-myeloma-due-to-perturbation-of-the-endoplasmic-reticulum-stress-pathway/

Related Journal Article

http://dx.doi.org/10.18632/oncotarget.27493

Tags: cancerCarcinogensMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Time Pressure Impact on Finnish Home Care Nurses

October 31, 2025

Diabetes Fatalism: Impact on Outcomes in African Americans

October 31, 2025

Assessing Ergonomics in Special Needs Kindergarten Settings

October 31, 2025

Prenatal Probiotics: Boosting Neonatal Gut Development

October 31, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1293 shares
    Share 516 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    202 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    136 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary Methane Dry Reforming at Low Temperatures Using Oxygen-Vacancy-Enriched MgO/Ni@NiAlO Catalyst

Time Pressure Impact on Finnish Home Care Nurses

Empowering Cancer Care in Bangladesh Through Collaboration

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.